Abivax presents its 2025 results and outlook

On March 23, 2026, Abivax presented its financial results for 2025, while also providing an update on its business activities. The company has €530.4 million in cash and short-term investments as of December 31, 2025, ensuring the financing of operations until the fourth quarter of 2027. The results of the ABTECT Phase 3 study on obefazimod will be published at the end of Q2 2026.

Abivax also strengthened its leadership team, appointing Michael Nesrallah as Chief Commercial Officer. R&D spending reached €177.8 million, an increase due to the progress of clinical trials. General expenses rose due to higher personnel costs.

Despite the departure of Sofinnova Partners from the board of directors, Abivax's management maintains its confidence in its strategic priorities for the future.